Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;163(1):4-17.
doi: 10.1111/j.1476-5381.2011.01216.x.

β(2) -adrenoceptor agonists: current and future direction

Mario Cazzola  1 , Luigino Calzetta, Maria Gabriella Matera
Affiliations
Review

β(2) -adrenoceptor agonists: current and future direction

Mario Cazzola et al. Br J Pharmacol. 2011 May.

Abstract

Despite the passionate debate over the use of β(2) -adrenoceptor agonists in the treatment of airway disorders, these agents are still central in the symptomatic management of asthma and COPD. A variety of β(2) -adrenoceptor agonists with long half-lives, also called ultra long-acting β(2) -adrenoceptor agonists (ultra-LABAs; indacaterol, olodaterol, vilanterol, carmoterol, LAS100977 and PF-610355) are currently under development with the hopes of achieving once-daily dosing. It is likely that the once-daily dosing of a bronchodilator would be a significant convenience and probably a compliance-enhancing advantage, leading to improved overall clinical outcomes. As combination therapy with an inhaled corticosteroid (ICS) and a LABA is important for treating patients suffering from asthma, and a combination with an inhaled long-acting antimuscarinic agent (LAMA) is important for treating COPD patients whose conditions are not sufficiently controlled by monotherapy with a β(2) -adrenoceptor agonist, some novel once-daily combinations of LABAs and ICSs or LAMAs are under development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of salmeterol, formoterol and emerging ultra-LABAs.
See this image and copyright information in PMC

References

    1. Agarwal SK, Marshall GD., Jr Beta-adrenergic modulation of human type-1/type-2 cytokine balance. J Allergy Clin Immunol. 2000;105:91–98. - PubMed
    1. Aldridge RE, Hancox RJ, Taylor DR, Cowan JO, Winn MC, Frampton CM, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med. 2000;161:1459–1464. - PubMed
    1. Aparici M, Gómez-Angelats M, Vilella D, Cortijo J, Morcillo EJ, Carcasona C, et al. The in vitro pharmacological profile of LAS100977 – a potent, selective and long-acting beta-2 receptor agonist [abstract] Am J Respir Crit Care Med. 2010;181:A5675.
    1. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM. Long-acting β2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;3:CD001104. - PMC - PubMed
    1. Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis. 2010;5:311–318. - PMC - PubMed

MeSH terms

Substances